Literature DB >> 9566674

Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation.

B A Hart1, R A Bank, J A De Roos, H Brok, M Jonker, H M Theuns, J Hakimi, J M Te Koppele.   

Abstract

The objective of this study was to analyse parameters in rhesus monkey collagen-induced arthritis (CIA) with which the inflammation and destruction of the joints can be described in quantitative terms. CIA was induced in genetically susceptible and resistant monkeys, which can be distinguished on the basis of the dominant resistance marker Mamu-A26. The disease course was monitored daily using a semiquantitative scoring system. Plasma samples were collected once or twice weekly and analysed for C-reactive protein (CRP). Urines were collected overnight once a week and analysed for excretion rates of the collagen cross-links hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP). The results show that periods of active CIA are characterized by substantial weight loss and increased plasma CRP levels, followed shortly thereafter by increased excretion rates of the collagen cross-links HP and LP. Remission of the disease can be recognized by a decline in plasma CRP levels and especially an increase in body weight. The highest CRP levels were found in the most severely arthritic monkeys, indicating a possible relationship of the absolute plasma CRP levels to the severity of inflammation. During periods of active arthritis, increased excretion rates of collagen cross-links HP and LP in the urine were found. In particular, the major collagen cross-link in articular cartilage, HP, showed a strong increase (9- to 15-fold). The excretion rates of LP, which is considered as a bone-specific degradation marker, only increased 4- to 6-fold, thus indicating predominant destruction of cartilage and less of bone. In conclusion, the severity of CIA can be monitored in a quantitative manner using plasma CRP levels, urinary excretion rates of HP and LP, and body weights, superimposed on semiquantitative clinical scores. The parameters also facilitate a more objective assessment of the effect of anti-arthritic drugs in the model than with the clinical scores alone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9566674     DOI: 10.1093/rheumatology/37.3.314

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  15 in total

1.  Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys.

Authors:  H P Brok; J M Tekoppele; J Hakimi; J A Kerwin; E M Nijenhuis; C W De Groot; R E Bontrop; B A 't Hart
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 2.  Development of macromolecular prodrug for rheumatoid arthritis.

Authors:  Fang Yuan; Ling-dong Quan; Liao Cui; Steven R Goldring; Dong Wang
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

3.  Inflammation, immune reactivity, and angiogenesis in a severe combined immunodeficiency model of rheumatoid arthritis.

Authors:  Laurie S Davis; Marian Sackler; Ruth I Brezinschek; Ellis Lightfoot; Jennifer L Bailey; Nancy Oppenheimer-Marks; Peter E Lipsky
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

4.  Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031.

Authors:  Takeshi Ishikawa; Fusako Nishigaki; Susumu Miyata; Yoshitaka Hirayama; Kyoko Minoura; Junko Imanishi; Masahiro Neya; Tsuyoshi Mizutani; Yoshimasa Imamura; Yoichi Naritomi; Hidetsugu Murai; Yoshitaka Ohkubo; Akira Kagayama; Seitaro Mutoh
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

5.  Relationships between Cytokine Levels and Disease Parameters during the Development of a Collagen-induced Arthritis Model in Cynomolgus Macaques (Macaca fascicularis).

Authors:  Eun Wha Choi; Sungjoo Kim
Journal:  Comp Med       Date:  2019-05-08       Impact factor: 0.982

6.  Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis.

Authors:  M P M Vierboom; E Breedveld; Y S Kap; C Mary; N Poirier; B A 't Hart; B Vanhove
Journal:  Clin Exp Immunol       Date:  2015-12-16       Impact factor: 4.330

7.  Collagen-induced arthritis in common marmosets: a new nonhuman primate model for chronic arthritis.

Authors:  Michel P M Vierboom; Elia Breedveld; Ivanela Kondova; Bert A 't Hart
Journal:  Arthritis Res Ther       Date:  2010-10-26       Impact factor: 5.156

Review 8.  Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy.

Authors:  Brad Bolon; Marina Stolina; Caroline King; Scot Middleton; Jill Gasser; Debra Zack; Ulrich Feige
Journal:  J Biomed Biotechnol       Date:  2010-12-28

Review 9.  Modeling human arthritic diseases in nonhuman primates.

Authors:  Michel P M Vierboom; Margreet Jonker; Ronald E Bontrop; Bert 't Hart
Journal:  Arthritis Res Ther       Date:  2005-06-09       Impact factor: 5.156

10.  The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.

Authors:  Maarten Van Roy; Cedric Ververken; Els Beirnaert; Sven Hoefman; Joost Kolkman; Michel Vierboom; Elia Breedveld; Bert 't Hart; Sofie Poelmans; Lieselot Bontinck; Alex Hemeryck; Sandy Jacobs; Judith Baumeister; Hans Ulrichts
Journal:  Arthritis Res Ther       Date:  2015-05-20       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.